Drug Profile

SGN 35C

Alternative Names: 35C; PF-08046044; SGN-35C

Latest Information Update: 25 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Seagen
Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunotoxins
Mechanism of Action DNA topoisomerase I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Lymphoma

Most Recent Events

06 Dec 2025 Pharmacodynamics, efficacy, adverse events, pharmacokinetics data from a phase I trial in Lymphoma presented at the 67^th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
12 Feb 2024 Seagen plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) (IV) in May 2024 (NCT06254495)
14 Dec 2023 Seagen has been acquired by Pfizer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com